2-hydroxy-5-nitrophenylacetic acid | 51794-07-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxy-5-nitrophenylacetic acid
• 英文别名: 5-nitro-2-hydroxyphenylacetic acid；(2-hydroxy-5-nitro-phenyl)-acetic acid；(2-Hydroxy-5-nitro-phenyl)-essigsaeure；2-hydroxy-5-nitro-benzeneacetic acid；2-hydroxy-5-nitro-phenylacetic acid；2-(2-Hydroxy-5-nitrophenyl)acetic acid
• CAS: 51794-07-1
• 化学式: C₈H₇NO₅
• mdl: MFCD04117976
• 分子量: 197.147
• InChiKey: ORXCFNAIXBBSJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-hydroxy-5-nitrophenylacetic acid 180.0~185.0 ℃ 、8.0 kPa 条件下， 生成 5-硝基-1-苯并呋喃-2(3H)-酮
  参考文献：
  名称：

  Hill, American Chemical Journal, 1900, vol. 24, p. 9

  摘要：

  DOI：
• 作为产物：
  描述：

  1-溴-2-(溴甲基)-4-硝基苯 在 Cu catalyst 作用下， 生成 2-hydroxy-5-nitrophenylacetic acid
  参考文献：
  名称：

  Lisitsyn,V.N.; Lugovskaya,E.K., Journal of Organic Chemistry USSR (English Translation), 1974, vol. 10, p. 92 - 95

  摘要：

  DOI：

文献信息

• Npy antagonists, preparation and uses
  申请人：Botez Iuliana

  公开号：US20090233910A1

  公开（公告）日：2009-09-17

  The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

  本发明涉及新颖化合物，它们的制备和用途，特别是在治疗方面的用途。更具体地说，它涉及至少具有两个芳香环的衍生化合物，它们的制备和用途，特别是在人类或动物健康领域。这些化合物对存在于中枢和外周神经系统中的神经肽Y（NPY）的生物受体具有亲和力。本发明的化合物优选为NPY拮抗剂，更具体地说是NPY Y1亚型的拮抗剂，因此可用于治疗或预防涉及NPY的任何疾病。本发明还涉及含有所述化合物的药物组合物，其制备和用途，以及使用所述化合物的治疗方法。
• Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamates †
  作者：Bridget M. Sykes、Michael P. Hay、Dubravka Bohinc-Herceg、Nuala A. Helsby、Charmian J. O’Connor、William A. Denny

  DOI：10.1039/b000135j

  日期：——

  The rates and extent of release of a series of substituted anilines from 4-nitrobenzyl carbamates, following nitro group reduction by radiolytic, enzymic and chemical methods, are reported. The yield of released anilines decreased over the pH range 4–7, but was independent of the basicity of the leaving aniline. Detailed studies of the fragmentation of one example identified the 4-hydroxylamine as the key intermediate. At pH greater than 5 the released aniline 3b condenses with a reactive 4-iminoquinomethane intermediate 4a to give amine 26, thus depleting the measurable amount of aniline 3b released. At pH less than 5 the release of amine proceeds to completion. The efficiency of reductively triggered release of anilines 7 varied with small changes in the leaving group, but this was not uniformly related to aniline basicity. The competing reaction of the released aniline 3b to form amine 26 lowers the efficiency of release of 3b. This reaction occurs at the relatively high concentrations (50 μM) used in the study and indicates the released effector amine should be toxic at concentrations considerably lower than 50 μM. This highlights the need for prodrugs of very potent cytotoxic effectors to be used in tumour-directed nitroreductase enzyme-prodrug therapy.

  报告了通过放射性、酶和化学方法将硝基还原后，一系列取代苯胺从 4-硝基苄基氨基甲酸酯中释放出来的速率和程度。释放出的苯胺的产率在 pH 值为 4-7 的范围内下降，但与离开苯胺的碱性无关。对一个例子的碎裂过程进行的详细研究发现，4-羟胺是关键的中间体。当 pH 值大于 5 时，释放出的苯胺 3b 与反应性 4- 亚氨基喹啉甲烷中间体 4a 缩合，生成胺 26，从而消耗了可测量的苯胺 3b 释放量。当 pH 值小于 5 时，胺的释放会进行到底。还原触发释放苯胺 7 的效率随离去基团的微小变化而变化，但这与苯胺的碱性并不一致。释放出的苯胺 3b 发生竞争反应生成胺 26，从而降低了 3b 的释放效率。这种反应发生在研究中使用的相对较高的浓度（50 μM）下，表明释放的效应胺在浓度大大低于 50 μM 时就会产生毒性。这凸显了在肿瘤定向硝基还原酶酶促药物疗法中使用强效细胞毒性效应物质原药的必要性。
• Compositions and methods for enhancing drug delivery across biological membranes and tissues
  申请人：——

  公开号：US20020009491A1

  公开（公告）日：2002-01-24

  This invention provides compositions and methods for enhancing delivery of drugs and other agents across a biological barrier, including epithelial tissues such as the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 50 residues in length.

  本发明提供了增强药物和其他药剂跨越生物屏障的组合物和方法，包括上皮组织例如皮肤、胃肠道、肺上皮等。该组合物和方法也适用于通过内皮组织跨越血脑屏障。该组合物和方法采用了具有足够的鸟氨酸或酰胺基侧链基团的增强运输体，以增强化合物跨越组织的一个或多个层次的递送，相对于非结合化合物。增强递送的聚合物包括例如在6到50个残基之间的聚精氨酸分子。
• 一种2,5-二氨基苯乙醇的制备方法
  申请人：苏州盖德精细材料有限公司

  公开号：CN107892656A

  公开（公告）日：2018-04-10

  本发明公开了一种2,5‑二氨基苯乙醇的制备方法，包括以下步骤：将制得的5‑硝基‑2‑氨基苯乙酸溶解于乙醚中，加入FeCl3和MnO2，通入氮气，升温至80℃，常压下通入氢气，搅拌反应2‑3h，冷却后过滤，蒸除乙醚，将得到的固体重结晶后，既得所述2,5‑二氨基苯乙醇。该制备方法操作条件要求较低，稳定性好，产物收率较高。
• Investigation of novel 7,8-disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as potent Chk1 inhibitors
  作者：Lisa A. Hasvold、Le Wang、Magdalena Przytulinska、Zhan Xiao、Zehan Chen、Wen-Zhen Gu、Philip J. Merta、John Xue、Peter Kovar、Haiying Zhang、Chang Park、Thomas J. Sowin、Saul H. Rosenberg、Nan-Horng Lin

  DOI：10.1016/j.bmcl.2008.02.080

  日期：2008.4

  The synthesis and structure-activity relationships (SAR) of Chk1 inhibitors based on a 5,10-dihydro-dibenzo[b,e][1,4] diazepin-11-one core are described. Specifically, an exploration of the 7 and 8 positions on this previously disclosed core afforded compounds with improved enzymatic and cellular potency. (C) 2008 Elsevier Ltd. All rights reserved.